Paper Details

  1. Home
  2. Paper Details

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group.

Author: BrooksB R, CohenJ A, FordC C, GoldsteinJ, JohnsonK P, LisakR P, MyersL W, PanitchH S, RoseJ W, SchifferR B, VollmerT, WeinerL P, WolinskyJ S

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, Non-P.H.S.Research funding provided by US government agencies other than the Public Health Service.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

Glatiramer acetate for injection was well tolerated and safe, with significantly fewer relapses and neurological improvements in patients with relapsing-remitting multiple sclerosis.
Paper Details　
Original Abstract of the Article :
When 251 relapsing-remitting patients with multiple sclerosis were randomized to receive daily subcutaneous injections of glatiramer acetate, previously called copolymer 1 (Copaxone; n = 125) or placebo (n = 126) for 24 months, there were no laboratory abnormalities associated with glatiramer acetat...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1212/wnl.50.3.701

データ提供：米国国立医学図書館（NLM）

Glatiramer Acetate for Multiple Sclerosis: A Desert Oasis for Relapses

Multiple sclerosis (MS), a chronic inflammatory disease of the central nervous system, is like a vast desert, with its unpredictable relapses and debilitating symptoms. This study, like a caravan searching for an oasis of relief, investigates the long-term effects of glatiramer acetate (Copaxone), a medication used to treat relapsing-remitting MS. The researchers found that glatiramer acetate was well-tolerated and demonstrated sustained clinical benefit in reducing relapse rate and delaying the progression of disability.

A Beacon of Hope: Easing the Burden of Relapses

This study, like a beacon guiding a caravan through the desert, offers a glimmer of hope for individuals living with relapsing-remitting MS. The researchers found that glatiramer acetate significantly reduced the frequency of relapses, providing a much-needed reprieve from the unpredictable nature of the disease. This finding is akin to discovering a vital water source in the vast desert, offering a much-needed lifeline for those facing the harsh realities of MS.

A Path to Resilience: Navigating the Desert of MS

This research offers valuable insights into the potential of glatiramer acetate in managing the challenges of multiple sclerosis. By providing a means to reduce relapses and delay disability progression, glatiramer acetate empowers individuals to navigate the unpredictable desert of MS with greater resilience and hope.

Dr. Camel's Conclusion

This study underscores the importance of continuous research and development in finding effective treatments for chronic diseases like MS. By offering a beacon of hope in the form of glatiramer acetate, we can equip individuals with the tools they need to navigate the challenges of this disease and forge a path towards a more fulfilling life.
Date :
  1. Date Completed 1998-04-17
  2. Date Revised 2022-03-31
Further Info :

Pubmed ID

9521260

DOI: Digital Object Identifier

10.1212/wnl.50.3.701

Related Literature

Article Analysis
・Side Effects of glatiramer injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.